Konjac Mannan

Summary

Konjac Mannan (CHEMBL4297959) is a phase-3 clinical-stage unknown; indicated across 2 conditions including constipation disorder and obesity disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297959
Name	Konjac Mannan
Type	Unknown
Max phase	3

Also known as: Amorphophallus konjac root mannan, E-425, Glucomannan, Ins no.425, Ins-425, Konjac, Konjac glucomannan, Konjac mannan, Konjac-flour, Konnyaku, Konnyaleu, Nutricol gp 6220

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	3	MONDO:0002203	HP:0002019
obesity disorder	2	MONDO:0011122	EFO:0001073

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE4	4
PHASE2	4
Not specified	4
PHASE1	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01485718	PHASE4	UNKNOWN	Effect of Daily Glucomannan in Overweight Patients
NCT01495806	PHASE4	COMPLETED	Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood
NCT02280772	PHASE4	COMPLETED	Effect of Glucomannan Supplementation on Body Weight in Overweight and Obese Children
NCT02336438	PHASE4	COMPLETED	The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery
NCT01151878	PHASE3	COMPLETED	Glucomannan for Childhood Functional Constipation.
NCT00613600	PHASE2	COMPLETED	Safety and Effectiveness Study of a Fiber Supplement for Weight Loss
NCT01553500	PHASE2	COMPLETED	Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
NCT03741660	PHASE2	COMPLETED	Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM
NCT03741686	PHASE2	COMPLETED	Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome
NCT01709955	PHASE1	COMPLETED	The Effects of Glucomannan on Weight Loss
NCT01875627	PHASE1	COMPLETED	Satiety Study of a Carbohydrate Meal to a Highly Viscous Gel Meal
NCT02134938	PHASE1	UNKNOWN	Effects of Viscous Fibre Containing Foods on Satiety (Gel Form)
NCT07231003	Not specified	ACTIVE_NOT_RECRUITING	The Effect of Glucomannan Powder on Improving Gut Microbiota.
NCT00465036	Not specified	COMPLETED	Effect of Flaxseed on Lipid Uptake and Appetite
NCT02711306	Not specified	COMPLETED	Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome
NCT05850949	Not specified	UNKNOWN	The Effect of Konjac Grain in the Post-prandial Glycaemic Response of Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).